Title of article :
Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients
Author/Authors :
Karimi ، Narges Immunogenetics Research Center, School of Medicine - Mazandaran University of Medical Sciences , Boostani ، Reza Department of Neurology - School of Medicine - Mashhad University of Medical Sciences , Fatehi ، Farzad Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Panahi ، Akram Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Okhovat ، Ali Asghar Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Ziaadini ، Bentolhoda Department of Neurology - Kerman Neuroscience Research Center - Kerman University of Medical Science , Basiri ، Keivan Department of Neurology - School of Medicine - Isfahan University of Medical Sciences , Abdi ، Siamak Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Sinaei ، Farnaz Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Rezaei ، Mojtaba Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences , Shamsaei ، Gholamreza Neurology Department - Ahvaz Jundishapur University of Medical Sciences , Ansari ، Behnaz Department of Neurology - School of Medicine - Isfahan University of Medical Sciences , Nafissi ، Shahriar Department of Neurology - Shariati Hospital - Tehran University of Medical Sciences
Abstract :
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with Coronavirus Disease 2019 (COVID-19) infection. In this study, we described nine GBS patients following the COVID-19 vaccine. Methods: In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis. Results: The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements. Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.
Keywords :
Coronavirus , 2019 , Vaccine , Guillain , Barre syndrome , AstraZeneca , Sinopharm , Sputnik
Journal title :
Basic and Clinical Neuroscience
Journal title :
Basic and Clinical Neuroscience
